Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Sponsor: Genzyme, a Sanofi Company
A PHASE3 clinical study on Non Small Cell Lung Cancer, this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Feb 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genzyme, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amarillo, United States , Ancona, Italy , Ashford, Australia , Avellino, Italy , Baltimore, United States , Bandung, Indonesia , Bangalore, India , Bangkok, Thailand , Bedford Park, Australia , Beijing, China and 143 more locations